2004
DOI: 10.1097/01.all.0000136753.35948.c0
|View full text |Cite
|
Sign up to set email alerts
|

Mechanisms of immunotherapy: IgG revisited

Abstract: Successful immunotherapy is associated with quantitative and qualitative changes in the allergen-specific IgG antibody response. The induction of IgG antibodies with blocking activity may have a protective role not only through the inhibition of allergen-induced, IgE-mediated release of inflammatory mediators from mast cells and basophils, but also through the inhibition of IgE-facilitated antigen presentation to T cells. Qualitative changes in the allergen-specific IgG antibody response may possibly be an imp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

10
136
0
2

Year Published

2010
2010
2021
2021

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 175 publications
(150 citation statements)
references
References 51 publications
10
136
0
2
Order By: Relevance
“…Secondly, induction of PUTGAspecific Tregs or Th1 cells may help in the regulation, through bystander mechanisms (26), of Th2 responses directed against known TG allergens present in the same pollen particle. Thirdly, the regulation of PUTGA-specific Th2 responses may also result in downstream regulation of IgE and induction of blocking IgG antibody responses to known TG allergens, a hallmark of specific immunotherapy (SIT) treatment (27,28). Finally, induction of PUTGA-specific Th1 or Treg cells may lead to PUTGA-specific IgG production, which may interfere with IgE-induced mediator release and other immediate-type reactions by mechanisms such as steric hindrance, competition for antigen binding, and inhibitory signaling through FcγRIIB (29,30).…”
Section: Discussionmentioning
confidence: 99%
“…Secondly, induction of PUTGAspecific Tregs or Th1 cells may help in the regulation, through bystander mechanisms (26), of Th2 responses directed against known TG allergens present in the same pollen particle. Thirdly, the regulation of PUTGA-specific Th2 responses may also result in downstream regulation of IgE and induction of blocking IgG antibody responses to known TG allergens, a hallmark of specific immunotherapy (SIT) treatment (27,28). Finally, induction of PUTGA-specific Th1 or Treg cells may lead to PUTGA-specific IgG production, which may interfere with IgE-induced mediator release and other immediate-type reactions by mechanisms such as steric hindrance, competition for antigen binding, and inhibitory signaling through FcγRIIB (29,30).…”
Section: Discussionmentioning
confidence: 99%
“…41 Moreover, it might be more important to measure the blocking activity via in vitro assays at an allergen-specific level. 65,68 Shift of the Th1 / Th2 Cytokine Ratio…”
Section: Discussionmentioning
confidence: 99%
“…67 In addition to the increase of specific IgG4 levels, SIT increases the blocking activity of IgG on the allergen capture and cross-linking of mast cell and basophil Fcε-receptor bound IgE. 68 Moreover, IgG4 does not activate the complement system, has a lower affinity for Fcγ receptors, interferes with basophil histamine release and reduces antigen-specific T cell proliferation by prevention of IgE-facilitated allergen binding to B cells and subsequent antigen-presentation. 65,68 Formation of multivalent IgE-IgG-allergen complexes has been suggested to result in mast cell FcεRI autoinhibition.…”
Section: Allergen-specific Regulatory Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…The production of specific IgG antibodies to allergens, especially IgG4 subclass, is the most important immunological change induced by AIT [59][60][61][62]. However, in some studies there is a lack of correlation between increased IgG4 titres and clinical improvement [55], since the induction of IgG4 blocking antibodies may not be reflected in serum or other biological fluid samples, requiring bioassays as the inhibition of IgE-facilitated allergen presentation for its possible detection [63].…”
Section: Immunotherapy Follow-upmentioning
confidence: 99%